At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNTX Context Therapeutics Inc.
Trading 03-16 13:49:42 EDT
3.21
-0.15
-4.61%
High3.62Low3.19Vol1.20M
Open3.32D1 Closing3.36Amplitude12.80%
Mkt Cap294.47MTradable Cap127.79MTotal Shares91.88M
T/O4.11MT/O Rate3.01%Tradable Shares39.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes
TIPRANKS  ·  03-14 04:35
Context Therapeutics Adopts Shareholder-Friendly Board Governance Changes
Context Therapeutics voids classified board and for-cause director removal provisions in charter correction
Reuters  ·  03-14 04:10
Context Therapeutics voids classified board and for-cause director removal provisions in charter correction
Context Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Reuters  ·  03-11
Context Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections
TIPRANKS  ·  02-28
Context Therapeutics Reaches Governance Settlement, Plans Annual Elections
Context Therapeutics Inc. to Present at Key Investor Conferences
Reuters  ·  02-09
Context Therapeutics Inc. to Present at Key Investor Conferences
Context Therapeutics nimmt an mehreren Investorenkonferenzen teil
Reuters  ·  02-09
Context Therapeutics nimmt an mehreren Investorenkonferenzen teil
Context Therapeutics Highlights T Cell Engager Pipeline Strategy
TIPRANKS  ·  01-08
Context Therapeutics Highlights T Cell Engager Pipeline Strategy
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
Reuters  ·  2025-12-22
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn
Reuters  ·  2025-12-17
ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
THOMSON REUTERS  ·  2025-12-17
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials
Reuters  ·  2025-11-07
Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials
Context Therapeutics Reports Improved Quarterly Results
TIPRANKS  ·  2025-11-06
Context Therapeutics Reports Improved Quarterly Results
Context Therapeutics reports Q3 results and advances lead bispecific antibody trials
Reuters  ·  2025-11-06
Context Therapeutics reports Q3 results and advances lead bispecific antibody trials
Context Therapeutics Inc. Q3 Basic EPS USD -0.1
THOMSON REUTERS  ·  2025-11-06
Context Therapeutics Inc. Q3 Basic EPS USD -0.1
Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
TIPRANKS  ·  2025-10-28
Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing
Reuters  ·  2025-10-25
BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing
Context Therapeutics: Amends Sales Agreement, May Offer & Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing
THOMSON REUTERS  ·  2025-10-25
Context Therapeutics: Amends Sales Agreement, May Offer & Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing
Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025
Reuters  ·  2025-10-06
Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025
BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
Reuters  ·  2025-10-04
BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule
Reuters  ·  2025-10-04
Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule

Introduction

Company Name.
Context Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--